This site is intended for Healthcare Professionals only

Congratulations on completing this module  (0% complete)

quiz close icon

module menu icon Scenarios

Scenarios

Ms G has been using Gina for three months. Her symptoms have improved and she is now able to ride her bike again. When going through the Pharmacy Checklist, she tells you that since she purchased her last pack, she had a problem with one of her legs and has been told that she has a blood clot.

Can you supply Gina?

Mrs F asks if she would be suitable for Gina. Her GP has been prescribing intravaginal oestrogen creams for the past 6 months to manage her VA symptoms. She is happy with the symptom improvement she has experienced but she finds it difficult to take time off of work to go to her GP. She thinks that getting a similar product from pharmacy will be more convenient for her. She tells you that she is 60 years old and her last period was well over 5 years ago. There have been no changes to her or her family's health status since her last prescription and she has no contraindications to Gina.

Can you supply Gina?

NoShe should see her GP first to discuss as Gina may provide a lower dose than her current local oestrogen therapy

IncorrectWomen who have been using local oestrogen therapy for more than 3 months at the recommended dose and whose symptoms are adequately controlled can be switched to Gina and start on the maintenance dose. If symptom control is affected by a lower oestrogen dose she should discuss this with her GP

Return to Gina
learning home page

CLICK HERE

Pharmacy Team
Training Guide

DOWNLOAD

Pharmacy Guide for
the Supply of Gina

DOWNLOAD

Pharmacy
Checklist

DOWNLOAD

Click continue to assessment to answer some further questions to test your understanding and record this learning in your learning log.

Pharmacists and pharmacy technicians can use this training module to help support their GPhC revalidation.


Reference

1. Novo Nordisk. Pharmacy Guide for the Supply of Gina [2022]. https://www.medicines.org.uk/emc/rmm/2509/Document (accessed June 2024)

Further information about this product, including essential supply information, adverse reactions, precautions, contraindications, and method of use can be found at: https://www.emcpi.com/pi/41923